GSK plc has announced that its drug velzatinib has received Orphan Drug Designation (ODD) from Japan's Ministry of Health, Labour and Welfare for the treatment of gastrointestinal stromal tumors (GIST). This designation is a significant milestone for GSK as it continues to develop innovative treatments in oncology. The approval is based on promising data from the ongoing phase I/Ib StrateGIST 1 trial, which showcases velzatinib's anti-tumor activity and tolerability profile.

GSK, traded on the NYSE under the ticker GSK, is a global biopharmaceutical company focused on developing medicines that address significant health challenges. The company operates under the SIC code 2834, which pertains to Pharmaceutical Preparations. Recent filings include multiple 6-K forms, with the latest one dated November 19, 2026, detailing the ODD for velzatinib.

The filing states, "Velzatinib has been granted ODD in Japan, supported by data showing promising anti-tumor activity and a tolerability profile." This designation complements the drug's existing US FDA Fast Track designation and ODDs in both the US and EU, indicating a strong regulatory path forward for the drug.

The impact of this designation may be felt across the pharmaceutical industry, particularly among companies focused on oncology. GSK's commitment to accelerating the development of velzatinib, with ongoing phase III trials in first- and second-line GIST, reflects a strategic move to capture a share of the market for rare cancer treatments. The filing notes that enrollment in the second-line clinical trial is ahead of schedule, demonstrating strong interest from the GIST community.

Looking ahead, GSK plans to share additional data for velzatinib at the Connective Tissue Oncology Society (CTOS) Annual Meeting 2026 in Seoul, South Korea. This meeting will feature seven abstracts, including clinical analyses of velzatinib, which will further support its development across various KIT mutations and lines of therapy.

With the recent ODD in Japan, GSK is poised to strengthen its oncology portfolio and address the significant unmet needs in GIST treatment. The company continues to focus on developing differentiated medicines that improve outcomes for patients facing challenging cancers.